Document Detail


Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
MedLine Citation:
PMID:  22484209     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
P-glycoprotein belongs to the ATP binding cassette transporters, responsible for the multidrug resistance of cancer cells. These transporters efflux hydrophobic drugs outside cells and decrease their therapeutic efficacy. The aim of this study was to investigate the effect of vandetanib, an oral tyrosine kinase inhibitor of EGFR, VEGFR 2 and RET kinases, on the functionality of P-gp after a 24h-treatment at therapeutic concentration (2μM), and its ability to increase the cytotoxicity of chemotherapeutic agents in multidrug resistance cancer cells. In this study we found that IGROV1-DXR and IGROV1-CDDP cells were resistant to doxorubicin and cisplatin respectively, compare to parental cell line IGROV1. The parental sensitive and the two resistant cell lines similarly expressed MRP1 and did not express BCRP. Moreover, in contrast to the IGROV1 and IGROV1-CDDP cells, IGROV1-DXR cell line overexpressed P-gp. Functional activity studies demonstrated that MRP1 was not functional and the MDR phenotype in IGROV1-DXR cells was linked to P-gp functionality. Results also showed that vandetanib reversed resistance to doxorubicin in IGROV1-DXR cells, but not to cisplatin in IGROV1-CDDP cells. After 24h of treatment, vandetanib increased the accumulation of rhodamine 123 and calcein AM, demonstrating a functional inhibition of the transporter. In IGROV1-DXR cell line, vandetanib reverse resistance to doxorubicin by inhibiting the functionality of P-gp. In conclusion, vandetanib should be an option for drug combination in patients already developing a P-gp mediated multidrug resistance.
Authors:
C Jovelet; J Bénard; F Forestier; R Farinotti; J M Bidart; S Gil
Related Documents :
15340009 - The role of myosin heavy chain phosphorylation in dictyostelium motility, chemotaxis an...
22293659 - Treatment with the parp-inhibitor pj34 causes enhanced doxorubicin-mediated cell death ...
3779849 - Multiple forms of acid phosphatase and their differential secretion during stalk format...
14985429 - Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pat...
2319489 - Effect of extracellular ions on motility and cell entry in toxoplasma gondii.
25351499 - Assessment of caroverine as a potential chemotherapeutical agent in hnscc cell lines.
22537919 - Immediate and long-term impacts of potassium permanganate on photosynthetic activity, s...
23287709 - In vitro evaluation of biomarkers for cisplatin-induced nephrotoxicity using hk-2 human...
6571789 - Influences of clotting factors (thrombin, factor xiii) and of fibronectin on the growth...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-30
Journal Detail:
Title:  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences     Volume:  -     ISSN:  1879-0720     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-4-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9317982     Medline TA:  Eur J Pharm Sci     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier B.V. All rights reserved.
Affiliation:
Univ Paris-sud 11, Faculté de Pharmacie, Laboratoire de Pharmacie Clinique EA4123, Chatenay-Malabry, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Is the evidence for the use of subglottic drainage to prevent ventilated-associated pneumonia suffic...
Next Document:  Ex vivo models to evaluate the role of ocular melanin in trans-scleral drug delivery.